Core Viewpoint - Iovance Biotherapeutics experienced a nearly 6% decline in stock price due to a downgrade in analyst recommendation, despite a generally positive market day for equities [1]. Group 1: Analyst Downgrade - UBS analyst David Dai changed his recommendation for Iovance from buy to neutral and significantly lowered the price target from $17 to $2 per share [2]. - This downgrade followed the release of the company's latest quarterly earnings, which provided insights into its performance [4]. Group 2: Product Performance Concerns - Sales of Iovance's leading product, the advanced melanoma drug Amtagvi, were reported to be below expectations, indicating a slower commercialization ramp-up [5]. - There are concerns regarding higher drop-out rates for Amtagvi, suggesting potential flaws in patient selection [5]. Group 3: Revenue Guidance and Market Sentiment - The company issued a notable revenue guidance cut in its earnings report, raising concerns among investors about its future performance [6]. - Despite the scientific potential of Iovance and Amtagvi, the current business aspects warrant caution among investors [6].

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. for alleged violations of federal securities laws, following a significant decline in the company's financial performance and misleading statements made to investors [1][2][3]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter [4]. - The company's full fiscal year 2025 revenue guidance was reduced from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. Allegations - The lawsuit claims that Iovance's executives provided overly positive statements while concealing material adverse facts about the company's growth potential and its ability to meet demand for its treatments [3]. Legal Proceedings - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, are encouraged to join the class action lawsuit, with a deadline to request lead plaintiff status by July 14, 2025 [2][5]. Representation - Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis, meaning they will only collect fees if the case is successful [6][7].

Group 1 - A shareholder class action lawsuit has been filed against Iovance Biotherapeutics, alleging materially false and misleading statements regarding the company's business and operations [1] - The lawsuit claims that new Authorized Treatment Centers (ATCs) are facing longer timelines to begin treating patients with Amtagvi, which has led to inefficiencies in patient identification and selection [1] - These dynamics have resulted in higher costs and lower revenue for Iovance, as ATCs are unable to keep pace with the manufactured product [1] Group 2 - Shareholders who purchased Iovance shares between May 9, 2024, and May 8, 2025, and experienced significant losses are encouraged to discuss their legal rights [2] - The deadline to request appointment as lead plaintiff in the case is July 14, 2025 [3] - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) between August 8, 2024, to May 8, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Karthik Trichur Sundaram v. Iovance Biotherapeutics, Inc., et al. (Case No. 3:25-cv-04177) has been commenced in the United States Dist ...

Core Viewpoint - Iovance Biotherapeutics is a small-cap biotech company trading below $2 per share, which some analysts believe is undervalued despite recent setbacks in revenue guidance and operational challenges [2][5][7]. Group 1: Company Performance - Iovance received approval for its first product, Amtagvi, for metastatic melanoma, marking a significant regulatory milestone [4]. - The company reported $49.3 million in revenue for the first quarter, a notable increase from the previous year, but revised its annual revenue guidance down to $250 million to $300 million from an earlier estimate of $450 million to $475 million [5][9]. - The decline in revenue guidance was attributed to overestimating the growth of authorized treatment centers (ATCs) necessary for administering TIL-based therapies [6][7]. Group 2: Market Potential - Analysts estimate a consensus price target of $19.58 for Iovance, indicating substantial upside potential from current levels [8]. - If Iovance achieves the midpoint of its revised revenue guidance at $275 million, it would be competitive for a newly launched medicine [9]. - The company is pursuing international approvals for Amtagvi, which could expand its market significantly, with potential annual sales exceeding $2 billion at peak [10]. Group 3: Risks and Challenges - The complexity of manufacturing and administering Amtagvi through specialized ATCs increases operational costs compared to simpler therapies [11]. - Clinical setbacks in ongoing studies could negatively impact the company's stock price, making it a risky investment despite its current low valuation [12].

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]

Core Insights - Iovance Biotherapeutics is under investigation for potential violations of federal securities laws and unlawful business practices [1] - The company reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million, down from $73.7 million in the previous quarter [3] - Iovance has revised its full fiscal year 2025 revenue guidance from a range of $450 million-$475 million to $250 million-$300 million, representing a reduction of over 40% at the midpoint [3] - Following the announcement, Iovance's share price dropped by $1.42, or approximately 44%, closing at $1.75 on May 9, 2025 [3] Company Performance - The first quarter 2025 product revenue of $49.3 million indicates a significant decrease compared to the previous quarter's revenue of $73.7 million [3] - The revision of the full-year 2025 revenue guidance reflects challenges in the launch dynamics of the T cell immunotherapy, Amtagvi (lifileucel), which was launched in the U.S. in the first half of 2024 [3] Market Reaction - The announcement of the revenue decline and guidance revision led to a sharp decline in Iovance's stock price, falling from $3.17 to $1.75 within a day [3]

SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- In a dramatic turn for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), investors watched the company's shares plunge nearly 44% on May 9, 2025, after the San Carlos-based cell therapy pioneer reported a first-quarter revenue miss that sharply contradicted earlier upbeat assurances from management. Hagens Berman is now investigating whether Iovance violated U.S. securities laws and urges Iovance investors who suffered substantial losses to submit your losses now. ...

Core Insights - Iovance Biotherapeutics experienced a significant stock decline on May 9 following a disappointing first-quarter earnings report, with a loss of $0.36 per share compared to the consensus estimate of a $0.24 loss [1] - The company's revenue for Q1 was reported at $49.3 million, which fell short of the expected $81.53 million [1] Financial Performance - The earnings per share (EPS) loss of $0.36 indicates a larger loss than analysts had anticipated [1] - Revenue of $49.3 million represents a substantial shortfall from the forecasted revenue of $81.53 million, highlighting potential operational challenges [1]

Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not re ...